作者:Jing Zhang、Audrey Chan、Blaise Lippa、Jason B. Cross、Christopher Liu、Ning Yin、Jan Antoinette C. Romero、Jonathan Lawrence、Ryan Heney、Prudencio Herradura、Jennifer Goss、Cynthia Clark、Cassandra Abel、Yanzhi Zhang、Katherine M. Poutsiaka、Felix Epie、Mary Conrad、Azard Mahamoon、Kien Nguyen、Ajit Chavan、Edward Clark、Tong-chuan Li、Robert K. Cheng、Michael Wood、Ole A. Andersen、Mark Brooks、Jason Kwong、John Barker、Ian Barrie Parr、Yugui Gu、M. Dominic Ryan、Scott Coleman、Chester A. Metcalf
DOI:10.1016/j.bmcl.2017.03.006
日期:2017.4
The emergence and spread of multidrug-resistant (MDR) Gram negative bacteria presents a serious threat for public health. Novel antimicrobials that could overcome the resistance problems are urgently needed. UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) is a cytosolic zinc-based deacetylase that catalyzes the first committed step in the biosynthesis of lipid A, which is essential for the survival of Gram-negative bacteria. Our efforts toward the discovery of novel LpxC inhibitors are presented herein. (C) 2017 Elsevier Ltd. All rights reserved.